contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


biovica-signs-new-work-order-with-us-biotech-company-for-tka-testing-services

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Biovica International is a pharmaceutical company that focuses its research on cancer treatment. The company develops blood-based biomarker tests to monitor and evaluate cancer treatments. The tests analyze the risk of developing the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main focus is on the treatment of breast cancer. Biovica International was founded in 2008 and is headquartered in Uppsala.

Biovica International

Biovica, active in blood-based cancer monitoring, has secured a new work order (WO) valued at SEK 2.5 million for TKa testing services within its Pharma Services business. This marks the third...

<div class="mfn-preamble"><p><strong>Biovica, active in blood-based cancer monitoring, has secured a new work order (WO) valued at SEK 2.5 million for TKa testing services within its Pharma Services business. This marks the third work order signed with this customer, bringing the total value of the three orders to SEK 7 million.</strong></p></div><div class="mfn-body"><p>The customer, a clinical-stage biotech company based on the US East Coast, specializes in developing small molecule medicines for oncology targets. Biovica has a Master Service Agreement (MSA) in place with the customer and Biovica’s TKa biomarker is currently being used in two ongoing Phase I clinical trials with this customer, each evaluating different drugs within the CDK inhibitor family. This latest work order, scheduled to run for 1.5 years starting in Q3 2025, adds a third drug candidate and clinical study to the collaboration, further strengthening the long-term partnership.</p><p>“We are excited to continue expanding our collaboration with this innovative biotech company. The ongoing trials, with multiple drugs running in parallel, show the broad applicability of our TKa biomarker in oncology development. With this new trial, TKa will be utilized in 16 different studies, increasing the likelihood of TKa being validated as a companion biomarker for patient treatment monitoring and optimization. The volume and recurrence of these work orders make me confident about the future,” said Henrik Winther, SVP, Business Development at Biovica.</p></div><div class="mfn-footer mfn-50cffce9eda7"><p><strong class="mfn-heading-1">Contact</strong></p><hr><p>Anders Rylander, CEO<br>Phone: +46 76 666 16 47<br>E-mail:&nbsp;<a rel="noopener" href="mailto:anders.rylander@biovica.com">anders.rylander@biovica.com</a></p><p>Anders Morén, CFO<br>Phone: +46 73&nbsp;125 92 46<br>E-mail: <a rel="noopener" href="mailto:anders.moren@biovica.com">anders.moren@biovica.com</a></p></div><div class="mfn-footer mfn-about mfn-3dbc25e51d95"><p><strong class="mfn-heading-1">Biovica – Treatment decisions with greater confidence</strong></p><hr><p>Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: “Improved care for cancer patients.” Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: <a rel="noopener" href="http://www.biovica.com">www.biovica.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/84f7f37f-4fa6-431a-8f67-f1fab19497e8/biovica-signs-new-work-order-with-us-biotech-company-for-tka-testing-services.pdf" class="mfn-generated mfn-primary">Biovica signs new Work Order with US biotech company for TKa testing services</a></p></div>